Molecular Oncology (Jun 2023)
Engaging European society at the forefront of cancer research and care
- Michael Baumann,
- Julio Celis,
- Ulrik Ringborg,
- Manuel Heitor,
- Anton Berns,
- Tit Albreht,
- Jeliazko Arabadjiev,
- Michael Boutros,
- Mario Brandenburg,
- Helena Canhao,
- Fatima Carneiro,
- Christine Chomienne,
- Francesco De Lorenzo,
- Alexander M. M. Eggermont,
- Angel Font,
- Elena Garralda,
- Margarida Goulart,
- Rui Henrique,
- Mark Lawler,
- Lena Maier‐Hein,
- Francoise Meunier,
- Simon Oberst,
- Pedro Oliveira,
- Maria Papatriantafyllou,
- Joachim Schüz,
- Eric Solary,
- Alfonso Valencia,
- Rosalia Vargas,
- Elisabete Weiderpass,
- Nils Wilking
Affiliations
- Michael Baumann
- German Cancer Research Center (DKFZ) Heidelberg Germany
- Julio Celis
- European Academy of Cancer Sciences Stockholm Sweden
- Ulrik Ringborg
- European Academy of Cancer Sciences Stockholm Sweden
- Manuel Heitor
- European Academy of Cancer Sciences Stockholm Sweden
- Anton Berns
- European Academy of Cancer Sciences Stockholm Sweden
- Tit Albreht
- National Institute of Public Health of Slovenia Ljubljana Slovenia
- Jeliazko Arabadjiev
- Clinic of Medical Oncology University Hospital Acibadem City Clinic Tokuda Sofia Bulgaria
- Michael Boutros
- European Academy of Cancer Sciences Stockholm Sweden
- Mario Brandenburg
- Federal Ministry of Education and Research (BMBF) Berlin Germany
- Helena Canhao
- Comprehensive Health Research Center (CHRC), NOVA Medical School Universidade Nova de Lisboa Portugal
- Fatima Carneiro
- European Academy of Cancer Sciences Stockholm Sweden
- Christine Chomienne
- Université de Paris France
- Francesco De Lorenzo
- European Academy of Cancer Sciences Stockholm Sweden
- Alexander M. M. Eggermont
- European Academy of Cancer Sciences Stockholm Sweden
- Angel Font
- La Caixa Foundation Barcelona Spain
- Elena Garralda
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain
- Margarida Goulart
- Joint Research Center, European Commission Brussels Belgium
- Rui Henrique
- Department of Pathology & Cancer Biology & Epigenetics Group – Research Center of IPO Porto (CI‐IPOP)/RISE@CI‐IPOP (Health Research Network) Portuguese Oncology Institute of Porto (IPO‐Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (P.CCC Raquel Seruca) Portugal
- Mark Lawler
- European Academy of Cancer Sciences Stockholm Sweden
- Lena Maier‐Hein
- Intelligent Medical Systems (IMSY) German Cancer Research Center (DKFZ) Heidelberg Germany
- Francoise Meunier
- European Academy of Cancer Sciences Stockholm Sweden
- Simon Oberst
- Quality and Accreditation Organisation of European Cancer Institutes Brussels Belgium
- Pedro Oliveira
- Nova School of Business and Economics Copenhagen Business School & Patient Innovation Frederiksberg Denmark
- Maria Papatriantafyllou
- Molecular Oncology FEBS Press Cambridge UK
- Joachim Schüz
- European Academy of Cancer Sciences Stockholm Sweden
- Eric Solary
- European Academy of Cancer Sciences Stockholm Sweden
- Alfonso Valencia
- Barcelona Supercomputing Center (BSC) Barcelona Spain
- Rosalia Vargas
- Ciencia Viva Lisbon Portugal
- Elisabete Weiderpass
- European Academy of Cancer Sciences Stockholm Sweden
- Nils Wilking
- Karolinska Institutet Stockholm Sweden
- DOI
- https://doi.org/10.1002/1878-0261.13423
- Journal volume & issue
-
Vol. 17,
no. 6
pp. 925 – 945
Abstract
European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.
Keywords
